Company Bacmedpharm Srl with Fiscal Code 35775603
recorded a turnover of 2024 of
41.167,
with a net profit of
26.837
and having an average number of employees of
1.
The company operates in the field of Intermedieri în comerţul cu produse diverse having the NACE code 4619.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Bacmedpharm Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
-
27.416
33.427
43.367
36.890
36.399
39.765
43.038
48.505
41.167
Total Income - EUR
-
27.416
33.427
43.367
36.890
36.400
39.765
43.038
48.505
41.167
Total Expenses - EUR
-
7.726
9.835
8.844
10.106
2.004
640
10.615
13.854
13.927
Gross Profit/Loss - EUR
-
19.690
23.593
34.523
26.784
34.396
39.125
32.423
34.652
27.240
Net Profit/Loss - EUR
-
19.101
23.259
34.090
26.415
33.384
38.016
32.001
34.176
26.837
Employees
-
1
1
1
1
1
0
1
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales decreased by -14.7%, from 48.505 euro in the year 2023, to 41.167 euro in 2024.
The Net Profit decreased by -7.148 euro, from 34.176 euro in 2023, to 26.837 in the last year.
Check the financial reports for the company - Bacmedpharm Srl
Financial Rating - BACMEDPHARM SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Bacmedpharm Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Bacmedpharm Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Bacmedpharm Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
37.823 euro in 2024 which includes Inventories of
0 euro, Receivables of
18.321 euro and cash availability of
19.502 euro.
The company's Equity was valued at
26.885 euro, while total Liabilities amounted to
10.938 euro.
Equity decreased by -7.148 euro, from 34.225 euro in 2023, to 26.885 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Bacmedpharm Srl